Goldman Sachs Downgrades Revance Therapeutic (RVNC) to Neutral, 'disappointing preliminary 4Q23 results and '24 outlook for Daxxify'
Tweet Send to a Friend
(Updated - January 9, 2024 8:24 AM EST)
Goldman Sachs analyst Chris Shibutani downgraded Revance Therapeutic (NASDAQ: RVNC) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Chris Shibutani downgraded Revance Therapeutic (NASDAQ: RVNC) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
